Verve Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	34,736	33,395	24,204	20,950
Revenue Growth (YoY)	41.14%	37.97%	15.53%	-
Cost of Revenue	28,289	27,626	20,729	16,711
Gross Profit	6,447	5,769	3,475	4,239
Selling, General & Admin	10,608	10,657	7,188	3,674
Research & Development	1,795	1,629	1,414	2,353
Other Operating Expenses	31.73	32.01	84.26	61.07
Operating Expenses	13,270	13,260	9,240	6,431
Operating Income	-6,823	-7,491	-5,765	-2,192
Interest Expense	-68.78	-75.21	-111.46	-90.38
Interest & Investment Income	1,116	882.5	416.19	184.31
Earnings From Equity Investments	-	-	450.91	-
Currency Exchange Gain (Loss)	-292.74	-294.52	-26.07	-192.62
Other Non Operating Income (Expenses)	301.43	278.64	88.37	40.21
EBT Excluding Unusual Items	-5,767	-6,699	-4,947	-2,250
Gain (Loss) on Sale of Investments	-48.56	-48.56	-17,438	-2,572
Gain (Loss) on Sale of Assets	2.74	18.87	-34.48	-16.88
Pretax Income	-5,813	-6,729	-22,419	-4,839
Income Tax Expense	-	-	-	10.75
Earnings From Continuing Operations	-5,813	-6,729	-22,419	-4,850
Earnings From Discontinued Operations	-	-	-28.89	-427.94
Net Income to Company	-5,813	-6,729	-22,448	-5,278
Minority Interest in Earnings	-	-	28.63	73.21
Net Income	-5,813	-6,729	-22,419	-5,205
Net Income to Common	-5,813	-6,729	-22,419	-5,205
Shares Outstanding (Basic)	22	22	11	1
Shares Outstanding (Diluted)	22	22	11	1
Shares Change (YoY)	62.73%	94.61%	1170.53%	-
EPS (Basic)	-258.63	-312.82	-2028.25	-5982.53
EPS (Diluted)	-258.63	-313.00	-2028.61	-5982.53
Free Cash Flow	-5,461	-8,030	-4,290	-2,779
Free Cash Flow Per Share	-242.95	-373.28	-388.10	-3194.52
Gross Margin	18.56%	17.27%	14.36%	20.23%
Operating Margin	-19.64%	-22.43%	-23.82%	-10.46%
Profit Margin	-16.73%	-20.15%	-92.63%	-24.84%
Free Cash Flow Margin	-15.72%	-24.04%	-17.72%	-13.27%
EBITDA	-6,301	-6,983	-4,915	-1,631
EBITDA Margin	-18.14%	-20.91%	-20.30%	-7.79%
D&A For EBITDA	522.76	508.23	850.4	560.71
EBIT	-6,823	-7,491	-5,765	-2,192
EBIT Margin	-19.64%	-22.43%	-23.82%	-10.46%
Advertising Expenses	-	116.88	156.95	46.43

Source: S&P Global Market Intelligence. Standard template. Financial Sources.